Elmwood Wealth Management, Inc. - XENON PHARMACEUTICALS INC ownership

XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 131 filers reported holding XENON PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.

Quarter-by-quarter ownership
Elmwood Wealth Management, Inc. ownership history of XENON PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$343,958
-11.3%
10,0690.0%0.17%
-8.3%
Q2 2023$387,657
-27.8%
10,069
-32.8%
0.18%
-28.7%
Q1 2023$536,636
-9.2%
14,9940.0%0.25%
-13.9%
Q4 2022$591,213
+9.3%
14,9940.0%0.30%
+9.3%
Q3 2022$541,000
+18.6%
14,9940.0%0.27%
+4.2%
Q2 2022$456,000
-0.4%
14,9940.0%0.26%
+10.2%
Q1 2022$458,000
-18.9%
14,994
-17.1%
0.24%
-12.6%
Q4 2021$565,000
+61.9%
18,080
-3.5%
0.27%
+46.2%
Q2 2021$349,000
+4.2%
18,7290.0%0.18%
-9.8%
Q1 2021$335,000
+42.6%
18,7290.0%0.20%
+6.8%
Q3 2020$235,0000.0%18,7290.0%0.19%0.0%
Q2 2020$235,000
-99.7%
18,7290.0%0.19%
+117.0%
Q1 2020$91,772,000
+37205.7%
18,7290.0%0.09%
-58.9%
Q4 2019$246,000
+45.6%
18,7290.0%0.21%
+25.1%
Q3 2019$169,000
-8.6%
18,7290.0%0.17%
+4.3%
Q2 2019$185,000
-2.6%
18,7290.0%0.16%
-6.8%
Q1 2019$190,000
+61.0%
18,7290.0%0.18%
+54.4%
Q4 2018$118,000
-100.0%
18,7290.0%0.11%
-44.4%
Q3 2018$247,223,000
-6.4%
18,729
-50.0%
0.20%
-14.6%
Q2 2018$264,078,000
+187.8%
37,458
+100.0%
0.24%
+172.7%
Q1 2018$91,772,00018,7290.09%
Other shareholders
XENON PHARMACEUTICALS INC shareholders Q4 2021
NameSharesValueWeighting ↓
COMMODORE CAPITAL LP 1,594,932$48,518,00010.26%
GREAT POINT PARTNERS LLC 1,104,334$33,594,0008.06%
ACUTA CAPITAL PARTNERS, LLC 272,500$8,289,0004.62%
DAFNA Capital Management LLC 438,623$13,343,0003.64%
Parkman Healthcare Partners LLC 294,559$8,960,0003.30%
Avoro Capital Advisors LLC 4,900,000$149,058,0002.94%
Nan Fung Group Holdings Ltd 114,380$3,479,0002.39%
BVF INC/IL 1,597,966$48,610,0002.35%
SILVERARC CAPITAL MANAGEMENT, LLC 232,630$7,077,0002.18%
DRIEHAUS CAPITAL MANAGEMENT LLC 4,391,038$133,575,0002.16%
View complete list of XENON PHARMACEUTICALS INC shareholders